Larry M. Lopez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Latest Publications
- 1 June 2006
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 40 (6) , 1172-1173
The Wild Ride: Cardiology and Clinical Pharmacy 1967–2005
- 1 June 2006
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 40 (6) , 1172-1173
The Wild Ride: Cardiology and Clinical Pharmacy 1967–2005
- 1 July 2005
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 45 (4) , 503-513
Rosuvastatin: A High-Potency HMG-CoA Reductase Inhibitor
- 1 July 2005
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 45 (4) , 503-513
Rosuvastatin: A High-Potency HMG-CoA Reductase Inhibitor
- Open Access
- 1 July 2003
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 60 (suppl_3) , S8-S14
Clinical challenges of bleeding in percutaneous coronary intervention
Larry M. Lopez, Pharm.D., FCCP; Clinical challenges of bleeding in percutaneous coronary intervention, American Journal of Health-System Pharmacy, Volume 60, I
- 1 July 2003
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 60 (suppl_3) , S8-S14
Open AccessClinical challenges of bleeding in percutaneous coronary intervention
Larry M. Lopez, Pharm.D., FCCP; Clinical challenges of bleeding in percutaneous coronary intervention, American Journal of Health-System Pharmacy, Volume 60, I
- 15 June 2002
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 59 (12) , 1173-1179
Managing hyperlipidemia: Current and future roles of HMG-CoA reductase inhibitors
The current and future roles of statins as antilipemic agents for the prevention and management of coronary artery disease (CAD) are reviewed. Therapy with hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) substantially reduces total cholesterol and low-density-lipoprotein (LDL) cholesterol concentrations. Large clinical trials have documented the efficacy of statin therapy for both primary and secondary prevention of CAD. Nevertheless, many eligible patients are either untreated or inadequately treated with these agents. In one study, 61% of patients with documented CAD were not treated with a lipid-lowering agent. Large percentages of high-risk patients receiving such agents are not meeting cholesterol goals set by the National Cholesterol Education Program (NCEP). Populations at increased risk for coronary events include patients with diabetes, women, the elderly, and patients with established CAD. Comparative studies have not shown any one agent as clearly superior to the others. Future possibilities for statin use include early treatment of hypercholesterolemia and acute coronary syndromes consistent with guidelines established by NCEP. Many clinicians now believe that an aggressive approach to lowering LDL cholesterol may yield even greater reductions in coronary events. Treatment may reduce the risk of recurrent ischemic events when initiated within 96 hours of hospitalization for acute myocardial infarction or unstable angina and continued for up to four months. Another use may be the management of atherosclerotic cerebrovascular disease. Closer attention to potential adverse effects will be necessary before any expansion in statin use. Statins are highly effective for improving cardiovascular outcomes in high-risk patients but are frequently underused. Pharmacists can help extend the benefits of statins to more patients.
- 15 June 2002
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 59 (12) , 1173-1179
Managing hyperlipidemia: Current and future roles of HMG-CoA reductase inhibitors
The current and future roles of statins as antilipemic agents for the prevention and management of coronary artery disease (CAD) are reviewed. Therapy with hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) substantially reduces total cholesterol and low-density-lipoprotein (LDL) cholesterol concentrations. Large clinical trials have documented the efficacy of statin therapy for both primary and secondary prevention of CAD. Nevertheless, many eligible patients are either untreated or inadequately treated with these agents. In one study, 61% of patients with documented CAD were not treated with a lipid-lowering agent. Large percentages of high-risk patients receiving such agents are not meeting cholesterol goals set by the National Cholesterol Education Program (NCEP). Populations at increased risk for coronary events include patients with diabetes, women, the elderly, and patients with established CAD. Comparative studies have not shown any one agent as clearly superior to the others. Future possibilities for statin use include early treatment of hypercholesterolemia and acute coronary syndromes consistent with guidelines established by NCEP. Many clinicians now believe that an aggressive approach to lowering LDL cholesterol may yield even greater reductions in coronary events. Treatment may reduce the risk of recurrent ischemic events when initiated within 96 hours of hospitalization for acute myocardial infarction or unstable angina and continued for up to four months. Another use may be the management of atherosclerotic cerebrovascular disease. Closer attention to potential adverse effects will be necessary before any expansion in statin use. Statins are highly effective for improving cardiovascular outcomes in high-risk patients but are frequently underused. Pharmacists can help extend the benefits of statins to more patients.